Morphosys Archives

$jp morgan biotech conference san fracisco morphosys$

News and Trends 18 Jan 2016

Inside Biotech’s Most Secretive Elite Conference: MorphoSys Talks on Investor Speed Dating in California

MorphoSys is the Biggest Biotech in Germany, and second biggest in Europe – so it is no wonder they were selected for access to the exclusive J.P.Morgan Conference in San-Francisco last week. Here, the MorphoSys team, which included Claudia Gutjahr-Löser and the CEO Simon Moroney, give you a sneak-insiders look into one of the most elite Biotech […]

January 18, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

morphosys multiple myeloma immunooncology mor202

News and Trends 7 Dec 2015

Best-in-Class Label for Blood Cancer Trial by Billion Euro Biotech

Latest results of MorphoSys candidate for Multiple Myeloma show that it was Celgene’s loss when it abandoned the phase I/IIa trial partnership on blood cancer. Announced at the American Society of Hematology (ASH) Annual Meeting this weekend in Orlando (US), the phase I/IIa drug for blood cancer from MorphoSys has shown good tolerability for this […]

December 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

interview simon moroney labiotech bio europe

News and Trends 2 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys

BIO-Europe is also a great opportunity to meet with top people from EU’s Biotech ecosystem. I had the chance to interview Simon Moroney, the CEO and one of the founders of MorphoSys (part of our top 9 EU-based billion euros Biotechs). The Munich-based company was founded in 1992 and now counts +-350 employees for a market […]

November 2, 2015 - 1 minutemin - By Philip Hemme

News and Trends 15 Sep 2015

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it … Talking about billon-dollar companies in the US is such a hype. Even the Wall street journal has its own start-up club (which btw is stunning). By looking at it, I wondered which European Biotechs were worth over €1Bn in Europe. […]

September 15, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 […]

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

A $500 Million Deal to Reactivate T-cells’ Anti-cancer Response

Heptares Therapeutics, the GPCR-targeted drug company, and British pharma giant AstraZeneca entered a new collaboration under which AstraZeneca will acquire exclusive global rights on the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate. Tumour cells have evolved mechanisms to evade the immune system, including through the production of a natural molecule called adenosine. By stimulating […]

August 10, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 23 Jul 2015

MorphoSys’ blood disorder antibody reaches Phase I

MorphoSys AG seems to be sitting on a goldmine with its Human Combinatorial Antibody Library (HuCAL). The German giant snatched the second milestone payment from Novartis this year. The latter will now initiate a Phase I test for a HuCAL antibody designed to treat blood disorders. MorphoSys landed some big accounts in the past. Pfizer, Bayer, […]

July 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 23 Jul 2015

Biotech investors are back in Germany

Things are looking good for German Biotechs! At least, this is what the general mood at the international congress organized by the IZB on July 16th and 17th 2015 in Martinsried, near Munich, reflected. A bunch of international investors and decision makers gathered to show that the sector is picking up momentum again in Germany! The Innovation and Startup […]

July 23, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us